J & J, Roche, Teva, Bristol-Myers Squibb, Amgen, Onyx Pharmaceuticals
-MarketWatch reported that Johnson & Johnson Innovation announced several new collaborations in the European region to coincide with a ‘Celebration of Life Science Innovation’ event. Johnson & Johnson Innovation Celebrates Life Science Innovation emphasizes Johnson & Johnson’s dedication to collaborations based on early-stage science with the potential to lead to transformative products for patients.
-Reuters reports that Roche has great news for lung cancer patients. Roche Immunotherapy Drug May be ‘Game Changer’ in Lung Cancer details the experimental Roche drug that, according to researchers, seems to work well for normally difficult-to-treat patients.
-A new contraceptive option has been approved by the FDA and launched by Teva reports PharmaLive. Teva Launches Quartette in US describes the new contraceptive tablets as well as Teva’s dedication to providing affordable birth control to women.
-The Bristol-Myers Squibb skin cancer drug Yervoy extends the lives of patients by as much as 10 years according to Bloomberg. Bristol’s Yervoy Adds Up to 10 Years of Life for Cancer Patients states that Yervoy is designed to fight cancer by removing molecular brakes that prevent immune system cells from destroying tumors.
-Biotech drugmaker Amgen announced that it has successfully completed its previously announced tender offer to purchase all outstanding shares of common stock of Onyx Pharmaceuticals. Amgen Successfully Completes Onyx Pharmaceuticals Tender Offer states that the acquisition of Onyx fits with Amgen’s commitment to advancing medicines for cancer patients around the world.
